Medical Device Registration in China

NMPA sets classification rules, technical standards, registration policies, and post-market surveillance requirements. The Center for Medical Device Evaluation (CMDE) conducts technical review for Class II and III devices; provincial NMPA offices handle Class I record filings.

Devices are classified Class I (low risk), Class II (moderate risk), or Class III (high risk). The NMPA classification catalog and online databases should be checked first. If classification is unclear, a formal classification application to NMPA is required before dossier work begins.

Class I manufacturers confirm the applicable product code via the NMPA catalog, published Class I lists, or a formal classification request. The dossier, called a Class I Record Filing, includes risk analysis, Clinical Evaluation Report, Product Technical Requirement (PTR), test reports, and design and manufacturing documentation.

Provincial NMPA performs a completeness check only; there is no full CMDE technical review. Accepted filings receive a Record Number that must appear on the Instructions for Use and labelling. Published filing information must be updated through modification applications when the device or PTR changes.

Class II and III submissions require comprehensive CMDE review. Dossiers typically include PTR, test reports, clinical data (where applicable), biocompatibility evaluations, risk analysis, manufacturing information, QMS proof (such as ISO 13485), and NMPA-specific research reports.

Before submission, confirm the device code and classification. Each code maps to a product category (similar in concept to FDA product codes) covering everything from laser instruments to vascular implants.

Test reports must demonstrate conformity with the PTR. Since Order No. 739, self-testing reports may be accepted in some circumstances, but foreign manufacturers usually test at NMPA-authorised Chinese laboratories because self-testing rules emphasise domestic QMS audit capability that rarely applies offshore.

Authorised test centres each hold an NMPA-approved scope; selection must match the device category. Testing information is submitted in Simplified Chinese. Typical in-country testing costs range roughly USD 5,000–20,000 per device family, with timelines often around six months depending on queue and product complexity.

Class II and III devices require clinical data unless listed on NMPA clinical evaluation exemption catalogues. Acceptable sources include China GCP-compliant trials, foreign trials with ethnic applicability justification, or predicate-device Clinical Evaluation Reports with manufacturer authorization for unpublished data.

Predicate CER routes look efficient but often fail when equivalency data is incomplete or the NMPA requests additional trials during review. China trials require Ethics Committee approval, hospital contracts, and local NMPA trial record filing before patient enrolment.

After completeness check and registration fee payment, CMDE conducts technical review. Reviewers commonly issue one round of supplementary information requests, with up to one year to respond satisfactorily. Novel or high-risk devices may face Expert Panel Meetings before or during review.

Official NMPA review timelines for imported devices include roughly 60 working days CMDE technical evaluation for Class II and 90 working days for Class III, plus acceptance, administrative review, and certificate issuance stages. Registration fees for imported Class II/III devices are substantial (often CNY 210,000–308,800 depending on category).

Innovative devices with significant clinical value and China core-technology IP may qualify for the Green Channel, with qualification confirmation in about 60 working days and priority review if designated as an “innovative medical device”.

The Agent acts as the regulatory contact for imported devices: submitting applications, responding to CMDE queries, maintaining the registration certificate, and supporting post-market obligations including adverse event reporting and renewal filings.

Agents also support recall coordination, technical service arrangements, and interface with distributors and hospitals. Choosing an Agent with device-category experience and responsive CMDE communication is as important as dossier quality. Registration maintenance continues for the life of the product in market.

Class II and III registration certificates are valid for five years. Renewal extensions must be submitted at least six months before expiry if the approved product remains unchanged. Changes to design, manufacturing site, models, or labelling require modification notifications or change applications and may trigger PTR updates or re-testing.

Post-market obligations include adverse event reporting (including global events for products sold in China), periodic safety updates where applicable, and compliance with Unique Device Identification (UDI) and labelling rules. Class I filings do not expire but require modification filings when published device information changes.

All devices sold in China require Simplified Chinese labelling and Instructions for Use. Translations must be medically precise, not literal, covering indications, contraindications, warnings, and operating steps understood by local clinicians.

Registration is only one gate. Importers still need compliant distributors, hospital tender channels where applicable, and alignment with entity business scope if the local company also handles importation, storage, or technical service.